What is it?
Growth hormone-releasing factor analog
Peptide Library · checked July 17, 2026
Sermorelin
FDA once approved Geref sermorelin products, then found their discontinuation was not for safety or effectiveness reasons. That historical approval belongs to those products and uses. It does not make today's sermorelin material equivalent to Geref or create an approved anti-aging use.
TL;DR
The lowdown
Four answers first. The source record follows.
What do humans show?
Limited pediatric growth evidence does not establish adult wellness outcomes
Where does FDA stand?
Listed among discontinued drug products
What is known—and not?
The historical and pediatric record does not provide a complete benefit-risk picture for adult wellness use or unidentified products. Effects mediated through the growth-hormone axis can require individual clinical assessment.
U.S. status · July 17, 2026
Approval, compounding, product, sport.
- FDA approval
- Historical Geref approvals remain on FDA's discontinued-product list; no FDA-approved anti-aging indication
- U.S. federal record
- Historical Geref approvals remain on FDA's discontinued-product list; no FDA-approved anti-aging indication
- Product identity
- Reviewed named-product record: Geref (sermorelin acetate).
- Sport
- No WADA status recorded in the reviewed source.
This reports the dated federal and sport record. It does not determine whether a particular product or transaction complies with state or federal law, and it is not legal advice.
01
What it is
Sermorelin is an analog of growth hormone-releasing factor. FDA records document approved Geref sermorelin acetate products that were later discontinued from marketing.
Two facts can both be true: the historical products were approved, and the current online category is not automatically the same product, use, or approval.
02
What humans actually show
- Historical clinical context: A 1999 review describes limited research in prepubertal children with idiopathic growth hormone deficiency.
- Outcome limits: The 1999 review said final adult height had not been determined and noted the available comparisons did not establish equivalence to somatropin.
- Population transfer: Pediatric growth research does not establish anti-aging, muscle, fat-loss, sleep, or general vitality benefits in adults.
- Product transfer: A historical New Drug Application does not authenticate the formulation, strength, manufacturing controls, or performance of a different current product.
03
FDA and U.S. status
FDA determined in 2013 that several Geref sermorelin acetate products were not withdrawn for safety or effectiveness reasons. The same notice says they remain in the Discontinued Drug Product List.
The historical record covers two New Drug Applications with different uses: NDA 19-863 for the 0.05 mg diagnostic formulation and NDA 20-443 for the treatment product approved in 1997. Neither is a current anti-aging approval.
“Not withdrawn for safety or effectiveness” answers why those products left the market. It is not a new approval, an anti-aging indication, or evidence that every sermorelin product is the same as Geref.
04
Risks and warning limits
The historical and pediatric record does not provide a complete benefit-risk picture for adult wellness use or unidentified products. Effects mediated through the growth-hormone axis can require individual clinical assessment.
PepCurrent does not provide dosing, sourcing, switching, or personalized treatment advice.
05
What would change this answer
- Any current FDA-approved sermorelin product or labeling action
- Better adult controlled trials tied to clearly defined outcomes
- Marketing that cites the 2013 discontinuation notice as if it were a current approval
- Product-identity claims that do not connect the marketed product to Geref
06
Sources and records
- FDA approval package for Geref diagnostic formulation, NDA 19-863
- FDA Federal Register notice on discontinued Geref products, 2013
- Prakash and Goa sermorelin clinical review, 1999
- FDA warning letter concerning online sermorelin products
Educational journalism only; not medical advice. We do not evaluate individual products or link vendors.
What changed
Corrected the cited clinical review from 2007 to 1999 and separated NDA 19-863 for the diagnostic formulation from NDA 20-443 for the treatment product.
What would change our answer
A current FDA approval or well-controlled adult trial tied to a defined product and outcome could change the answer. Historical discontinuation language alone cannot.
Version history · 2 entries
Boundary: PepCurrent explains public evidence and regulatory records. We do not evaluate individual products, recommend use, name vendors, or provide protocols.